Gefitinib
Therapeutic Group
Anti-neoplasticsIndication Dosage
Gefitinib is a medication used to treat certain types of lung cancer, specifically non-small cell lung cancer that has specific genetic changes called EGFR mutations. It helps slow down the growth of cancer cells in the lungs and can be prescribed when other treatments haven't been effective.
Treatment Of Locally Advanced Or Metastatic Non-small Cell Lung Cancer With Activating Mutations Of Epidermal Growth Factor Receptor:
- Adult: 250 Mg Once Daily
Content
- Tab: Gefitinib 250mg.
Pregnancy
Positive Evidence Of Risk: Avoid
Stability
- Tyrosine Kinase Inhibitor
Contra Indications
- Hypersensitivity To The Drug
Precautions
- Hypersensitivity To The Drug
Lactation
- Contraindicated. Discontinue Breast-feeding
Side Effects
- Alopecia
- Anorexia
- Asthenia
- Bone-marrow Suppression
- Blepharitis
- Conjunctivitis
- Diarrhoea
- Vomiting
- Dry Eye
- Dry Mouth
- Dry Skin
- Epistaxis
- Haematuria
- Interstitial Lung Disease (discontinue)
- Proteinuria
- Pruritus
- Acne
- Pyrexia
- Rash
- Skin Reactions
- Corneal Erosion
- Pancreatitis
- Nausea
- Oral Mucositis.
- Rare: Hepatitis
- Toxic Epidermal Necrolysis
- Hyperuricaemia
- Thromboembolism
- Tumour Lysis Syndrome.